Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide - PubMed (original) (raw)
Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide
Badreddine Kriem et al. FASEB J. 2005 Jan.
Abstract
Recent data have revealed that soluble oligomeric forms of amyloid peptide (Abeta) may be the proximate effectors of the neuronal injury and death occurring in Alzheimer's disease (AD). However, the molecular mechanisms associated with the neuronal cell death induced by the nonfibrillar Abeta remain to be elucidated. In this study, we investigated the role of the cytosolic Ca2+-dependent phospholipase A2 (cPLA2), and its associated metabolic pathway, i.e., the arachidonic acid (AA) cascade, in the apoptotic cell death induced by soluble oligomers of Abeta. The treatment of rat cortical neurons with low concentrations of soluble Abeta(1-40) or Abeta(1-42) peptide resulted in an early calcium-dependent release of AA associated with a transient relocalization of cPLA2. Both cPLA2 antisense oligonucleotides and a selective inhibitor of cPLA2 activity abolished the release of AA from neurons and also protected cells against apoptosis induced by Abeta. Furthermore, inhibitors of the PKC, p38, and MEK/ERK pathways that are involved in cPLA2 phosphorylation and activation reduced Abeta-induced cell death. Finally, we demonstrate that inhibitors of cyclooxygenase-2 reduced the Abeta-induced cell death by 55%. Our studies suggest a novel neuronal response of soluble oligomers of Abeta, which occurs through a cPLA2 signaling cascade and an AA-dependent death pathway. This may prove to be crucial in AD processes and could provide important targets for drug development.
Similar articles
- Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway.
Malaplate-Armand C, Florent-Béchard S, Youssef I, Koziel V, Sponne I, Kriem B, Leininger-Muller B, Olivier JL, Oster T, Pillot T. Malaplate-Armand C, et al. Neurobiol Dis. 2006 Jul;23(1):178-89. doi: 10.1016/j.nbd.2006.02.010. Epub 2006 Apr 19. Neurobiol Dis. 2006. PMID: 16626961 - The role of cytosolic phospholipase A2 α in amyloid precursor protein induction by amyloid beta1-42 : implication for neurodegeneration.
Sagy-Bross C, Kasianov K, Solomonov Y, Braiman A, Friedman A, Hadad N, Levy R. Sagy-Bross C, et al. J Neurochem. 2015 Mar;132(5):559-71. doi: 10.1111/jnc.13012. Epub 2015 Feb 3. J Neurochem. 2015. PMID: 25533654 - Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells.
Chalimoniuk M, Stolecka A, Cakała M, Hauptmann S, Schulz K, Lipka U, Leuner K, Eckert A, Muller WE, Strosznajder JB. Chalimoniuk M, et al. Acta Biochim Pol. 2007;54(3):611-23. Epub 2007 Aug 23. Acta Biochim Pol. 2007. PMID: 17713604 - Phospholipase A2 and arachidonic acid in Alzheimer's disease.
Sanchez-Mejia RO, Mucke L. Sanchez-Mejia RO, et al. Biochim Biophys Acta. 2010 Aug;1801(8):784-90. doi: 10.1016/j.bbalip.2010.05.013. Epub 2010 May 27. Biochim Biophys Acta. 2010. PMID: 20553961 Free PMC article. Review. - Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.
Schaeffer EL, Forlenza OV, Gattaz WF. Schaeffer EL, et al. Psychopharmacology (Berl). 2009 Jan;202(1-3):37-51. doi: 10.1007/s00213-008-1351-0. Epub 2008 Oct 14. Psychopharmacology (Berl). 2009. PMID: 18853146 Review.
Cited by
- Modulation of Cytosolic Phospholipase A2 as a Potential Therapeutic Strategy for Alzheimer's Disease.
André S, Verteneuil S, Ris L, Kahvecioglu ZC, Nonclercq D, De Winter J, Vander Elst L, Laurent S, Muller RN, Burtea C. André S, et al. J Alzheimers Dis Rep. 2023 Dec 29;7(1):1395-1426. doi: 10.3233/ADR-230075. eCollection 2023. J Alzheimers Dis Rep. 2023. PMID: 38225969 Free PMC article. - Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.
Schaeffer EL, Gattaz WF. Schaeffer EL, et al. Psychopharmacology (Berl). 2008 May;198(1):1-27. doi: 10.1007/s00213-008-1092-0. Epub 2008 Feb 19. Psychopharmacology (Berl). 2008. PMID: 18392810 Review. - Phospholipase d2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits.
Oliveira TG, Chan RB, Tian H, Laredo M, Shui G, Staniszewski A, Zhang H, Wang L, Kim TW, Duff KE, Wenk MR, Arancio O, Di Paolo G. Oliveira TG, et al. J Neurosci. 2010 Dec 8;30(49):16419-28. doi: 10.1523/JNEUROSCI.3317-10.2010. J Neurosci. 2010. PMID: 21147981 Free PMC article. - Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.
Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Patterson KR, et al. J Biol Chem. 2011 Jul 1;286(26):23063-76. doi: 10.1074/jbc.M111.237974. Epub 2011 May 6. J Biol Chem. 2011. PMID: 21550980 Free PMC article. - Cellular prion protein mediates early apoptotic proteome alternation and phospho-modification in human neuroblastoma cells.
Zafar S, Behrens C, Dihazi H, Schmitz M, Zerr I, Schulz-Schaeffer WJ, Ramljak S, Asif AR. Zafar S, et al. Cell Death Dis. 2017 Jan 19;8(1):e2557. doi: 10.1038/cddis.2016.384. Cell Death Dis. 2017. PMID: 28102851 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous